Drugs for Ankylosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 24)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Celecoxib |
Approved, Investigational |
Phase 4 |
|
169590-42-5 |
2662 |
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
2 |
|
Diclofenac |
Approved, Vet_approved |
Phase 4 |
|
15307-86-5 |
3033 |
Synonyms:
(2,6-Dichlorophenyl)amino]benzeneacetic acid
[2-(2,6-dichloroanilino)Phenyl]acetate
[2-(2,6-dichloroanilino)phenyl]acetic acid
[2-(2,6-dichloroanilino)Phenyl]acetic acid
[o-(2,6-Dichloroanilino)phenyl]acetic acid
{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
15307-81-0 (mono-potassium salt)
15307-86-5
2-((2,6-Dichlorophenyl)amino)benzeneacetate
2-((2,6-dichlorophenyl)amino)benzeneacetic acid
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid
2-(2,6-Dichloroanilino)phenylacetic Acid
2-(2,6-Dichlorophenylamino)phenylacetic acid
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid
2-[2-(2,6-dichloroanilino)phenyl]acetic acid
2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid
2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID
2b17
AC1L1F0T
Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)
AKOS001579542
Allvoran
Apo-Diclo
Assaren
Benfofen
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI)
BIDD:GT0380
BPBio1_000516
BRD-K08252256-236-05-6
BRN 2146636
BSPBio_000468
BSPBio_002169
C01690
Cataflam
CHEBI:47381
CHEMBL139
CID3033
cMAP_000014
D07816
D30801
D3748
DB00586
Delphimix
dichlofenac
Dichlofenac
Dichlofenal
Dichronic
Diclac
Diclobenin
diclofenac
Diclofenac
Diclofenac (INN)
Diclofenac [INN:BAN]
Diclofenac acid
Diclofenac Acid
Diclofenac potassium
Diclofenac Potassium
Diclofenac sodium
Diclofenac Sodium
Diclofenac, sodium
Diclofenaco
Diclofenaco [INN-Spanish]
Diclofenacum
Diclofenacum [INN-Latin]
Diclofenamic acid
Diclomelan
Diclonate P
Diclophenac
Diclo-Phlogont
Diclo-Puren
Diclord
Dicloreum
Dicloreuma
Dicrofenac
DIF
DivK1c_000272
DivK1c_000402
Dolobasan
Duravolten
Dyloject
Ecofenac
Effekton
|
EINECS 239-348-5
Feloran
GP-45,840
henyl)-o-aminophenylacetic acid
HMS2090C10
HMS501E04
HSDB 7234
I14-7739
IDI1_000272
IDI1_000402
ISV-205
KBio1_000272
KBio1_000402
KBio2_001410
KBio2_002306
KBio2_003978
KBio2_004874
KBio2_006546
KBio2_007442
KBio3_001389
KBio3_002786
KBioGR_001051
KBioGR_002306
KBioSS_001410
KBioSS_002308
Kriplex
Lopac0_000441
LS-11575
MolPort-000-003-072
N-(2,6-Dichlorop
NCGC00021125-01
Neriodin
NINDS_000272
NINDS_000402
Novapirina
Novo-Difenac
Novo-Difenac SR
Nu-Diclo
Oprea1_011155
Orthofen
Orthophen
Ortofen
Pennsaid
Prestwick0_000594
Prestwick1_000594
Prestwick2_000594
Prestwick3_000594
Primofenac
Prophenatin
ProSorb-D
Rhumalgan
SBB068617
Sodium diclofenac
Solaraze
Solaraze (TN)
Solaraze T
SPBio_001081
SPBio_002687
Spectrum_000930
Spectrum2_000991
Spectrum3_000385
Spectrum4_000506
Spectrum5_000867
SR 38
SR-38
STK984493
Transfenac
Tsudohmin
UNII-144O8QL0L1
UNM000001216103
Valetan
Voldal
Voltaflan
Voltaren
Voltaren Ophtha
Voltaren ophthalmic
Voltaren Ophthalmic
Voltaren Rapide
Voltaren SR
Voltaren-XR
Voltarol
Xenid
|
|
3 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
4 |
|
Analgesics |
|
Phase 4 |
|
|
|
5 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 4 |
|
|
|
6 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
7 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
8 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
9 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
10 |
|
Cholestyramine Resin |
|
Phase 4 |
|
|
|
11 |
|
Etanercept |
Approved, Investigational |
Phase 2, Phase 3 |
|
185243-69-0 |
|
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
etanercept
Etanercept
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
Etanercept (USAN/INN)
etanercept-szzs
|
etanercept-ykro
p75
p80 TNF-alpha receptor
Recombinant human TNF
rhu TNFR:Fc
rhu-TNFR:Fc
TNF-R2
TNFR-Immunoadhesin
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
|
|
12 |
|
Adalimumab |
Approved |
Phase 3 |
|
331731-18-1 |
16219006 |
Synonyms:
331731-18-1
Adalimumab
Adalimumab (genetical recombination)
Adalimumab (genetical recombination) (JAN)
Adalimumab (USAN/INN)
adalimumab-adaz
adalimumab-adbm
adalimumab-afzb
|
adalimumab-atto
adalimumab-bwwd
D02597
Humira
Humira (TN)
Humira Pen
Ig gamma-1 chain C region
|
|
13 |
|
tiludronate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
89987-06-4 |
60937 |
Synonyms:
(4-Chlorophenyl)thiomethylene bisphosphonic acid
(chloro-4-Phenyl)thiomethylene biphosphonate
(chloro-4-Phenyl)thiomethylene bisphosphonate
Acide tiludronique
Acide tiludronique [INN-French]
Acido tiludronico
Acido tiludronico [INN-Spanish]
Acidum tiludronicum
|
Acidum tiludronicum [INN-Latin]
CL2SMBP
Skelid
Tiludronate
Tiludronate disodium
Tiludronic acid
Tiludronic acid disodium salt
Tiludronic Acid Disodium Salt
|
|
14 |
|
Gastrointestinal Agents |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Nitisinone |
Approved, Investigational |
Phase 2 |
|
104206-65-7 |
115355 |
Synonyms:
104206-65-7
2-(2-nitro-4-(Trifluoromethyl)benzoyl)cyclohexane-1,3-dione
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
2-(2-nitro-4-Trifluoromethylbenzoyl)-1,3-cyclohexanedione
2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione
2-(a,a,a-trifluoro-2-nitro-P-Tuluoyl)-1,3-cyclohexanedione
2-(alpha,alpha,alpha-trifluoro-2-nitro-P-Tuluoyl)-1,3-cyclohexanedione
2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
2-(α,α,α-trifluoro-2-nitro-P-tuluoyl)-1,3-cyclohexanedione
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
AC1L3GZK
BIDD:PXR0129
C14H10F3NO5
CHEBI:50378
CHEMBL1337
CID115355
D05177
|
DB00348
FE-0200
LS-56815
nitisinona
Nitisinona
Nitisinone
Nitisinone (JAN/USAN/INN)
Nitisinone (NTBC)
Nitisinone [INN]
Nitisinone [USAN:INN]
nitisinonum
Nitisinonum
Nitisone
NTBC CPD
Orfadin
Orfadin (TN)
SC 0735
UNII-K5BN214699
|
|
18 |
|
Tyrosine |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
60-18-4 |
6057 |
Synonyms:
(-)-a-amino-P-Hydroxyhydrocinnamate
(-)-a-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-amino-P-Hydroxyhydrocinnamate
(-)-alpha-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoic acid
(S)-(-)-Tyrosine
(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid
(S)-2-amino-3-(P-Hydroxyphenyl)propionate
(S)-2-amino-3-(P-Hydroxyphenyl)propionic acid
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-3-(P-Hydroxyphenyl)alanine
(S)-a-amino-4-Hydroxybenzenepropanoate
(S)-a-amino-4-Hydroxy-benzenepropanoate
(S)-a-amino-4-Hydroxybenzenepropanoic acid
(S)-a-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-amino-4-Hydroxybenzenepropanoate
(S)-alpha-amino-4-Hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoic acid
(S)-Tyrosine
(S)-α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
140-43-2
1991-85-1
25619-78-7
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionic acid
2csm
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
46209-14-7
4-hydroxy-L-phenylalanine
4-Hydroxy-L-phenylalanine
4ts1
55520-40-6
60-18-4
93829_FLUKA
93829_SIGMA
AB1002647
AC-11295
AC1L1LPI
AC1Q4U7L
AC1Q4U7M
AI3-09055
alpha-Amino-beta-(4-hydroxyphenyl)propionic acid
AR-1J3457
BB_NC-1194
Benzenepropanoate
Benzenepropanoic acid
beta-(p-Hydroxyphenyl)alanine
bmse000051
C00082
CHEBI:17895
CHEMBL925
CID6057
D00022
DB00135
|
DB03839
DD69927C-C6A8-4BC6-8E9A-0AB423B176E7
DTY
EINECS 200-460-4
FEMA No. 3736
Free-Form L-Tyrosine
HSDB 2003
H-Tyr-OH
L Tyrosine
L-(-)-Tyrosine
L-2-Amino-3-p-hydroxyphenylpropanoic acid
L-p-Tyrosine
L-P-Tyrosine
LS-2336
L-Tyrosin
L-tyrosine
L-Tyrosine (9CI)
L-Tyrosine (JAN)
L-Tyrosine hydrochloride
L-Tyrosine, homopolymer
L-Tyrosine, monomer
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours
MolPort-001-792-016
NCGC00159350-02
NCGC00159350-03
nchembio.105-comp1
nchembio.121-comp7
nchembio.186-comp84
nchembio.284-comp7
nchembio816-comp11
NSC 82624
Para tyrosine
Para-tyrosine
p-Tyrosine
P-Tyrosine
Rxosine
T0550
T3754_SIAL
T4321_SIAL
T4321_SIGMA
T8566_SIGMA
tirosina
Tirosina
Tirosina [Spanish]
tyr
Tyr
TYR NH3+ COOH
tyrosine
Tyrosine
TYROSINE
Tyrosine (USP/INN)
Tyrosine (VAN)
Tyrosine [USAN:INN]
Tyrosine Power
Tyrosine, L- (8CI)
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Tyrosinum [Latin]
UNII-42HK56048U
W373605_ALDRICH
Y
|
|
19 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
20 |
|
Antibodies |
|
Phase 1 |
|
|
|
21 |
|
Antibodies, Monoclonal |
|
Phase 1 |
|
|
|
22 |
|
Infliximab |
Approved |
|
|
170277-31-3 |
|
Synonyms:
Ig gamma-1 chain C region
Infliximab (genetical recombination)
Infliximab-abda
Infliximab-axxq
|
Infliximab-dyyb
Infliximab-qbtx
Remicade
|
|
23 |
|
Dermatologic Agents |
|
|
|
|
|
24 |
|
Tea |
|
|
|
|
|
Interventional clinical trials:
(show all 49)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding |
Completed |
NCT03190603 |
Phase 4 |
Celecoxib |
2 |
Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial |
Completed |
NCT00715091 |
Phase 4 |
diclophenac;diclophenac |
3 |
Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS |
Unknown status |
NCT02809781 |
Phase 2, Phase 3 |
Etanercept |
4 |
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) |
Completed |
NCT00478660 |
Phase 3 |
adalimumab (Humira) |
5 |
Mechanism of Action Study of Anti-IL17 Treatment in Spondyloarthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling |
Completed |
NCT03358134 |
Phase 3 |
Secukinumab |
6 |
Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis |
Terminated |
NCT01617057 |
Phase 3 |
tiludronic acid;Placebo |
7 |
Arthrotomy With Irrigation and Debridement Versus Serial Arthrocentesis as Treatment for Septic Arthritis in Adults |
Withdrawn |
NCT00313365 |
Phase 3 |
|
8 |
Impact of Physical Therapy Program in Mouthbreathing Children After Adenotonsillectomy: Randomized Clinical Trial. |
Unknown status |
NCT02373553 |
Phase 1, Phase 2 |
|
9 |
Long-Term Clinical Trial of Nitisinone in Alkaptonuria |
Completed |
NCT00107783 |
Phase 2 |
Nitisinone (NTBC) |
10 |
The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth |
Withdrawn |
NCT02477358 |
Phase 1, Phase 2 |
|
11 |
Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells: Randomized Controlled Clinical Trial |
Unknown status |
NCT01357785 |
Phase 1 |
|
12 |
An Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Gimsilumab in Healthy Subjects and Subjects With Ankylosing Spondylitis |
Completed |
NCT04205851 |
Phase 1 |
KIN-1901;Placebo |
13 |
Performance of Pelvic Radiograph, CT -Scan and MRI of the Sacroiliac Joints to Diagnose Structural Sacroiliitis in a Large Cohort of Patients With Suspicion of Spondyloarthritis |
Unknown status |
NCT02888938 |
|
|
14 |
Selective Bilateral Laryngeal Reinnervation as a Secondary Treatment in Case of Bilateral Vocal Fold Paralysis: Analysis of Phonatory and Ventilatory Results |
Unknown status |
NCT02400008 |
|
|
15 |
Clinical and Radiological Outcomes of Centralization as a Surgical Management for Radial Club Hand |
Unknown status |
NCT03432052 |
|
|
16 |
An Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort) |
Unknown status |
NCT00237419 |
|
infliximab |
17 |
Transport Distraction Osteogenesis for Reconstruction of Ramus-Condyle Unit Following Release of Temporomandibular Joint Ankylosis |
Completed |
NCT04383964 |
|
|
18 |
CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System |
Completed |
NCT02425631 |
|
|
19 |
Total Temporomandibular Joint Replacement System Post Approval Study |
Completed |
NCT00762944 |
|
|
20 |
FUNCTIONAL LIMITATIONS DUE TO the FOOT INVOLVEMENT IN SPONDYLOARTHRITIS |
Completed |
NCT01833468 |
|
|
21 |
The Effect Of Platelet Rich Fibrin on Implant Stability |
Completed |
NCT02190409 |
|
|
22 |
Effect Of Anti TNF Alpha Therapy On Disease Activity And Bone Health, And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population |
Completed |
NCT01361542 |
|
anti TNF alpha agent;Anti TNF alpha therapy |
23 |
Hearing Aid Versus Surgical Rehabilitation as Treatment of Otosclerosis: Pilot Study |
Completed |
NCT02456272 |
|
|
24 |
Application of Virtual Mandibular Position in Temporomandibular Jont Reconstruction With Costochondral Graft in Children Jaw Deformity. |
Recruiting |
NCT03845088 |
|
|
25 |
Study of Validation of Measurements of the Movement of Stiff Treated Teeth and Orthodontic Corticotomy |
Recruiting |
NCT02337153 |
|
|
26 |
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components |
Recruiting |
NCT03576573 |
|
|
27 |
Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexelâ„¢ Total Elbow |
Recruiting |
NCT02469662 |
|
|
28 |
Actis Total Hip System 2 Year Follow-up |
Recruiting |
NCT02783274 |
|
|
29 |
International, Multicenter, Prospective Registry to Collect Data of Patients Treated With Alloplastic Total Temporomandibular Joint (TMJ) Replacements |
Recruiting |
NCT03991728 |
|
|
30 |
Studies on the Natural History and Pathogenesis of Spondyloarthritis |
Recruiting |
NCT01422694 |
|
|
31 |
Pre-surgical CT Scan Assessment of Femoral Head Bone Mineral Density Before Resection of Neurogenic Heterotopic Ossification (NHO) of the Hip |
Active, not recruiting |
NCT03914521 |
|
|
32 |
Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral Stems |
Active, not recruiting |
NCT02309593 |
|
|
33 |
Post Market Clinical Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts |
Active, not recruiting |
NCT02351414 |
|
|
34 |
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral Stems |
Active, not recruiting |
NCT02397746 |
|
|
35 |
Evolusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System |
Active, not recruiting |
NCT02074761 |
|
|
36 |
Contribution of EOS in the Structural Evaluation of Spondyloarthritis |
Active, not recruiting |
NCT03863756 |
|
|
37 |
Post Market Clinical Follow-up Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components |
Enrolling by invitation |
NCT02823834 |
|
|
38 |
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems |
Enrolling by invitation |
NCT02314702 |
|
|
39 |
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems |
Enrolling by invitation |
NCT02314611 |
|
|
40 |
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems |
Enrolling by invitation |
NCT02239783 |
|
|
41 |
Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components |
Enrolling by invitation |
NCT02149667 |
|
|
42 |
Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components |
Enrolling by invitation |
NCT02285842 |
|
|
43 |
Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem |
Not yet recruiting |
NCT04147559 |
|
|
44 |
The Use of Proximal Carpal Row Versus Iliac Crest Bone Graft in Total Wrist Fusion - a Randomized Controlled Multicenter Trial Comparing Two Operative Techniques (PROOF II - Trial) |
Not yet recruiting |
NCT04403958 |
|
|
45 |
Fatigue and Skeletal Muscle Impact in Severe Axial Spondylarthritis |
Not yet recruiting |
NCT03940911 |
|
|
46 |
Comparative Study Between Internal and External Distraction Osteogenesis in Lower Face Asymmetry |
Not yet recruiting |
NCT03540329 |
|
|
47 |
SI Joint Fusion and Decortication Using the SImmetry System |
Terminated |
NCT02560714 |
|
|
48 |
Evaluation of Circulating Osteogenic Factors in Trauma Patients (BMP-9) |
Terminated |
NCT01433536 |
|
|
49 |
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components |
Withdrawn |
NCT02507258 |
|
|
|